EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
EXELIXIS, INC.
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026
$62.68+0.45 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $16.28B
- P/E (TTM)
- 19.7
- Dividend yield
- –
Community
Notes and questions about Exelixis from other investors
No posts about EXEL yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.